Tibotec, TB Alliance in TMC207 deal

Tibotec Inc. granted the Global Alliance for TB Drug Development (New York, N.Y.) an exclusive, royalty-free, worldwide license to develop TMC207 to treat drug-susceptible tuberculosis. Tibotec will continue to develop the diarylquinoline (DARQ) antibiotic for multi-drug resistant tuberculosis (MDR-TB), an indication for which the compound is in Phase II testing (See BioCentury Extra, Wednesday, June 03, 2009). ...